{"id":2911,"date":"2024-02-29T11:01:18","date_gmt":"2024-02-29T08:01:18","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=2911"},"modified":"2024-02-29T13:05:09","modified_gmt":"2024-02-29T10:05:09","slug":"sanofi-turkiye-nadir-hastaliklar-gununde-erken-tani-ve-tedavinin-onemini-vurguluyor","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/sanofi-turkiye-nadir-hastaliklar-gununde-erken-tani-ve-tedavinin-onemini-vurguluyor\/","title":{"rendered":"Sanofi T\u00fcrkiye Nadir Hastal\u0131klar G\u00fcn\u00fc\u2019nde Erken Tan\u0131 ve Tedavinin \u00d6nemini Vurguluyor"},"content":{"rendered":"\n

Bug\u00fcn d\u00fcnyada milyonlarca insan nadir hastal\u0131klar ile m\u00fccadele ediyor.<\/em><\/strong>\u00dclkemizde ise yakla\u015f\u0131k 6 milyon ki\u015finin bu hastal\u0131klardan etkilendi\u011fi tahmin ediliyor.<\/em><\/strong>\u00a0<\/strong>Nadir hastal\u0131klar\u0131n te\u015fhisine ve tedavisine giden yolda fark\u0131ndal\u0131k son derece b\u00fcy\u00fck bir \u00f6neme sahip. Sanofi \u00d6zellikli Tedaviler T\u00fcrkiye, Levant ve \u0130ran Genel M\u00fcd\u00fcr\u00fc Pelin Yunuso\u011flu, Sanofi \u00d6zellikli Tedaviler T\u00fcrkiye, Levant ve \u0130ran Medikal Direkt\u00f6r\u00fc Dr. Nurdan Bulur ve Sanofi Nadir Hastal\u0131klar T\u00fcrkiye, \u0130ran ve Levant \u0130\u015f Birimi Direkt\u00f6r\u00fc Mine Say\u0131t \u00a0ile Sanofi\u2019de nadir hastal\u0131klar \u00fczerine yap\u0131lan \u00e7al\u0131\u015fmalar\u0131 konu\u015ftuk.<\/em><\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Sanofi \u00d6zellikli Tedaviler <\/em><\/strong>T\u00fcrkiye, Levant ve \u0130ran Genel M\u00fcd\u00fcr\u00fc Pelin Yunuso\u011flu<\/em><\/strong>\u00a0<\/em><\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

\u201cNadir Hastal\u0131klara yenilik\u00e7i \u00e7\u00f6z\u00fcmler geli\u015ftirmek ad\u0131na \u00e7al\u0131\u015f\u0131yoruz\u201d<\/em><\/strong><\/p>\n\n\n\n

Sanofi\u2019nin T\u00fcrkiye\u2019deki faaliyetleri nelerdir? \u00d6zellikli Tedaviler alan\u0131ndaki \u00e7al\u0131\u015fmalar\u0131n\u0131zdan k\u0131saca bahsedebilir misiniz?<\/strong>\u00a0<\/p>\n\n\n\n

Sanofi, T\u00fcrkiye\u2019de 65 y\u0131l\u0131 a\u015fk\u0131n bir ayak izine sahip. Uzun y\u0131llara dayanan biyoteknoloji deneyimimiz ile \u00f6zellikli tedaviler, genel ila\u00e7lar, a\u015f\u0131lar ve t\u00fcketici sa\u011fl\u0131\u011f\u0131 alanlar\u0131nda 275 farkl\u0131 \u00fcr\u00fcn ile hizmet veriyoruz<\/p>\n\n\n\n

Sanofi \u00d6zellikli Tedaviler\u2019in oda\u011f\u0131nda nadir hastal\u0131klar, nadir kan hastal\u0131klar\u0131, imm\u00fcnoloji, onkoloji ve hematoloji alanlar\u0131nda sundu\u011fumuz tedaviler yer al\u0131yor. Bunun yan\u0131 s\u0131ra s\u00fcrekli geli\u015ftirdi\u011fimiz \u00fcr\u00fcn portf\u00f6y\u00fcm\u00fcz ile bilimi ileri teknolojiyle birle\u015ftirerek toplum sa\u011fl\u0131\u011f\u0131n\u0131 iyile\u015ftirmek ve hastalar i\u00e7in yeni \u00e7\u00f6z\u00fcmler bulmak i\u00e7in \u00e7al\u0131\u015f\u0131yoruz. T\u00fcm d\u00fcnyada Nadir Hastal\u0131klar alan\u0131na liderlik eden ila\u00e7 firmas\u0131 olarak, hali haz\u0131rda nadir do\u011fumsal metabolik hastal\u0131klar grubunda olan lizozomal depo hastal\u0131klar\u0131na (LDH) odaklanarak, Gaucher, Fabry, Mukopolisakkaridozis tip 1, Pompe ve ASMD hastal\u0131klar\u0131 i\u00e7in tedavi \u00e7\u00f6z\u00fcmleri sunuyor ve yeni tedaviler \u00fczerinde \u00e7al\u0131\u015fmaya devam ediyoruz.<\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Sanofi <\/em><\/strong>Nadir Hastal\u0131klar <\/em><\/strong>T\u00fcrkiye, \u0130ran ve Levant \u0130\u015f Birimi Direkt\u00f6r\u00fc Mine Say\u0131t <\/em><\/strong><\/p>\n\n\n\n

\u201cNadir Hastal\u0131klar alan\u0131nda fark\u0131ndal\u0131\u011f\u0131 art\u0131rmak hedefiyle sekt\u00f6rde \u00f6nc\u00fc proje ve \u00e7al\u0131\u015fmalar y\u00fcr\u00fct\u00fcyoruz\u201d<\/em><\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

Nadir hastal\u0131klar konusunda fark\u0131ndal\u0131\u011f\u0131 art\u0131rmak kilit noktalardan biri. <\/strong>Sanofi bu anlamda nas\u0131l faaliyetler y\u00fcr\u00fct\u00fcyor?\u00a0\u00a0<\/strong><\/p>\n\n\n\n

Nadir olarak kategorize edilmesine ra\u011fmen toplumun % 5-8\u2019inin nadir hastal\u0131klardan birine sahip oldu\u011fu ve d\u00fcnya genelinde milyonlarca ki\u015finin bu hastal\u0131klardan etkilendi\u011fi biliniyor. \u00dclkemizde ise yakla\u015f\u0131k 6 milyon ki\u015finin bu hastal\u0131klardan etkilendi\u011fi tahmin ediliyor.  Yakla\u015f\u0131k %80\u2019i genetik k\u00f6kenli olan bu hastal\u0131klarda te\u015fhisin 8 y\u0131l\u0131 a\u015fk\u0131n s\u00fcrebilmesi ve olduk\u00e7a zor olmas\u0131 sebebiyle y\u00fcksek \u00f6l\u00fcm ve engellilik olu\u015fumu g\u00f6zlemleniyor. Bunun yan\u0131 s\u0131ra maalesef sa\u011fl\u0131k hizmetlerine eri\u015fim, sosyal ve t\u0131bbi destek uygulamalar gibi sorunlar da ya\u015fanabiliyor. M\u00fcracaat edilen bran\u015f say\u0131s\u0131 ve tan\u0131 s\u00fcrecinde uygulanan yanl\u0131\u015f tedaviler hastal\u0131k y\u00fck\u00fcn\u00fc art\u0131rabiliyor. Bu do\u011frultuda bizler de ba\u015fta \u00fclkemizin hizmetine sundu\u011fumuz yenilik\u00e7i tedaviler olmak \u00fczere, ileri teknolojilerle y\u00fcr\u00fctt\u00fc\u011f\u00fcm\u00fcz bilimsel \u00e7al\u0131\u015fmalar\u0131m\u0131z ve hastalar\u0131n ya\u015fam yolculuklar\u0131nda ya\u015fad\u0131klar\u0131 zorluklara \u00e7\u00f6z\u00fcm bulmay\u0131 hedefleyen projelerimizle, g\u00fc\u00e7l\u00fc payda\u015flarla i\u015f birlikleri kurarak \u00e7al\u0131\u015fmalar y\u00fcr\u00fct\u00fcyoruz. Amac\u0131m\u0131z hastalar\u0131n ya\u015famlar\u0131na ve \u00fclkemize de\u011fer katmak. Bilimin mucizelerinin pe\u015finde ko\u015farken, t\u00fcm \u00e7al\u0131\u015fmalar\u0131m\u0131z\u0131 alan\u0131nda s\u0131n\u0131f\u0131n\u0131n en iyisi ya da ilki olma hedefiyle y\u00fcr\u00fct\u00fcyoruz. <\/p>\n\n\n\n

Ankara \u00dcniversitesi ile verimli bir i\u015f birli\u011fi: NAD\u0130R<\/strong><\/p>\n\n\n\n

\u0130lk g\u00fcnden bug\u00fcne, hastalar ve hasta ihtiya\u00e7lar\u0131 her zaman oda\u011f\u0131m\u0131zda.\u202f Bu ihtiya\u00e7lar\u0131 daha iyi kar\u015f\u0131layabilmek i\u00e7in kurum, kurulu\u015f ve akademiler ile ba\u015far\u0131l\u0131 i\u015f birliklerine imza at\u0131yoruz.\u202f\u202fHastalar ve sa\u011fl\u0131k mesle\u011fi mensuplar\u0131 ile geli\u015ftirdi\u011fimiz e\u011fitim ve fark\u0131ndal\u0131k projeleriyle hastalara umut olmak ve onlar\u0131n ya\u015fam kalitelerini art\u0131rmak i\u00e7in \u00e7al\u0131\u015f\u0131yoruz.\u202f\u202f\u00dclkemizin sa\u011fl\u0131k politikas\u0131n\u0131 destekleyici \u00f6nemli i\u015f birliklerini, projeleri ve fark\u0131ndal\u0131k \u00e7al\u0131\u015fmalar\u0131n\u0131 hayata ge\u00e7iriyoruz. \u00d6rne\u011fin; Lizozomal Depo Hastal\u0131klar\u0131 alan\u0131nda modern tan\u0131 ve tedavi y\u00f6ntemlerine y\u00f6nelik ara\u015ft\u0131rmalar yapmak \u00fczere Ankara \u00dcniversitesi ile i\u015f birli\u011fi yap\u0131yor, Nadir Hastal\u0131klar Uygulama ve Ara\u015ft\u0131rma Merkezi NAD\u0130R\u2019in \u00e7al\u0131\u015fmalar\u0131na bilimsel destek sa\u011fl\u0131yoruz. Bu i\u015f birli\u011fi ile hastalar\u0131n tan\u0131, tedavi ve takip s\u00fcre\u00e7lerini geli\u015ftirmeyi hedefliyoruz.<\/a> <\/p>\n\n\n\n

Narin \u00c7ocuklar projemizle ise nadir\/kronik hastal\u0131k tan\u0131s\u0131 alm\u0131\u015f \u00e7ocuklara do\u011fru ilk yakla\u015f\u0131m ve sorumluluk s\u0131n\u0131rlar\u0131 konusunda akademik bilgilendirilme yap\u0131lmas\u0131, temel ve \u00f6zel ihtiya\u00e7lar\u0131na eri\u015fimlerinin kolayla\u015ft\u0131r\u0131lmas\u0131 ve e\u011fitim hayatlar\u0131n\u0131n uyum i\u00e7inde devaml\u0131l\u0131\u011f\u0131n\u0131n sa\u011flanmas\u0131na y\u00f6nelik faydalar elde etmeyi ama\u00e7lad\u0131\u011f\u0131m\u0131z bir pilot \u00e7al\u0131\u015fma ba\u015flatt\u0131k.\u202f\u00a0<\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Sanofi \u00d6zellikli Tedaviler T\u00fcrkiye<\/em><\/strong><\/a>, \u0130ran ve Levant<\/em><\/strong> Medikal Direkt\u00f6r\u00fc Dr. Nurdan Bulur <\/em><\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

\u201cCare4Rare\u2019in ilk faz\u0131 olan \u00e7al\u0131\u015ftay\u0131m\u0131z\u0131 ger\u00e7ekle\u015ftirdik\u201d<\/em><\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

Nadir hastal\u0131klar alan\u0131nda yap\u0131lan \u00f6ne \u00e7\u0131kan projelerinizden biri de Care4Rare. Projeyi ve yak\u0131n zamanda d\u00fczenledi\u011finiz \u00e7al\u0131\u015ftay\u0131 sizden dinleyebilir miyiz?<\/strong><\/a><\/p>\n\n\n\n

Care4Rare yine bu alanda hastalar\u0131n kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7lar\u0131n\u0131 g\u00f6z \u00f6n\u00fcnde bulundurarak PharmUp \u00e7at\u0131s\u0131 alt\u0131nda hayata ge\u00e7irdi\u011fimiz \u00f6nemli bir proje. Lizozomal Depo Hastal\u0131klar\u0131 ba\u015fta olmak \u00fczere nadir hastal\u0131\u011f\u0131 olan hastalar i\u00e7in hastal\u0131k fark\u0131ndal\u0131\u011f\u0131 ve tan\u0131dan ba\u015flayarak tedavi takip s\u00fcre\u00e7lerinde b\u00fct\u00fcn ihtiya\u00e7lar\u0131n\u0131n ortaya konulabilmesi, bu ihtiya\u00e7lar\u0131n giri\u015fimci ekosistemi ile payla\u015f\u0131lmas\u0131, sa\u011fl\u0131k oda\u011f\u0131nda \u00e7al\u0131\u015fan giri\u015fimcilerin bu ihtiya\u00e7lara y\u00f6nelik \u00e7\u00f6z\u00fcmler getirebilmesi i\u00e7in ba\u015flatt\u0131\u011f\u0131m\u0131z bir proje. Projenin temel hedefi ise ba\u015fta Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019n\u0131n Nadir Hastal\u0131klar Sa\u011fl\u0131k Strateji Belgesi ve Eylem Plan\u0131’nda belirtilen aksiyonlar olmak \u00fczere bu alanda hastalar\u0131n hayat\u0131na dokunan payda\u015flar\u0131n ihtiya\u00e7lar\u0131 do\u011frultusunda geli\u015ftirilebilecek yenilik\u00e7i dijital \u00e7\u00f6z\u00fcm, yakla\u015f\u0131m ve fikirlerin hayata ge\u00e7irilmesi.\u00a0<\/p>\n\n\n\n

Care4Rare kapsam\u0131nda proje ba\u015fvurular\u0131n\u0131 yapmak \u00fczere giri\u015fimcilere y\u00f6nelik a\u00e7\u0131lan \u00e7a\u011fr\u0131lar\u0131n hemen ard\u0131ndan ge\u00e7ti\u011fimiz g\u00fcnlerde ger\u00e7ekle\u015ftirdi\u011fimiz \u00e7ok payda\u015fl\u0131 \u00e7al\u0131\u015ftay ile proje i\u00e7in \u00f6nemli bir ad\u0131m att\u0131k. \u00c7al\u0131\u015ftayda \u00f6ncelikli ihtiya\u00e7lar\u0131 sa\u011fl\u0131k ekosisteminde yer alan t\u00fcm payda\u015flar\u0131m\u0131z\u0131n g\u00f6z\u00fcnden de\u011ferlendirme f\u0131rsat\u0131 bulduk ve \u00f6zellikle \u201cFark\u0131ndal\u0131\u011f\u0131n ve Bilgi D\u00fczeyinin Artt\u0131r\u0131lmas\u0131\u201d, \u201cHasta ve Hasta Yak\u0131nlar\u0131n\u0131n Desteklenmesi\u201d, \u201cNadir Hastal\u0131klar\u0131n Tan\u0131s\u0131\u201d ve \u201cTedavi ve Bak\u0131m Hizmetleri\u201d gibi 4 ba\u015fl\u0131k etraf\u0131nda yapay zek\u00e2, karar destek algoritmalar\u0131, mobil uygulamalar, uzaktan sa\u011fl\u0131k hizmetleri gibi teknolojilerin yan\u0131 s\u0131ra sa\u011fl\u0131k verilerinin etkin kullan\u0131m\u0131na ili\u015fkin konular\u0131 ele ald\u0131k. Belirlenen bu ihtiya\u00e7lar do\u011frultusunda haz\u0131rlad\u0131\u011f\u0131m\u0131z rapor geni\u015f bir giri\u015fimci havuzu ile payla\u015f\u0131lacak. Giri\u015fimcilerimiz de \u00e7al\u0131\u015ftay\u0131n \u00e7\u0131kt\u0131lar\u0131 \u0131\u015f\u0131\u011f\u0131nda \u00e7al\u0131\u015fmalar\u0131na y\u00f6n vererek hastalar\u0131n hayatlar\u0131n\u0131 kolayla\u015ft\u0131racak \u00e7\u00f6z\u00fcmler \u00fczerine \u00e7al\u0131\u015fmalar\u0131n\u0131 y\u00fcr\u00fctecekler.  <\/p>\n\n\n\n

Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Otizm, Zihinsel \u00d6zel Gereksinimler ve Nadir Hastal\u0131klar Dairesi Ba\u015fkan\u0131 Prof. Dr. Onur Burak Dursun ve Prof. Dr. B\u00fclent G\u00fcm\u00fc\u015fel\u2019in moderasyonu ile ger\u00e7ekle\u015fen \u00e7al\u0131\u015ftaya, Sa\u011fl\u0131k Hizmetleri Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc, T\u00fcrkiye T\u0131bbi \u0130la\u00e7 ve Cihaz Kurumu Halk Sa\u011fl\u0131\u011f\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc, Sa\u011fl\u0131\u011f\u0131n Geli\u015ftirilmesi Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc, T\u00fcrkiye Sa\u011fl\u0131k Hizmetleri Ba\u015fkanl\u0131\u011f\u0131 (T\u00dcSEB) ve Sosyal G\u00fcvenlik Kurumu yetkililerinin yan\u0131 s\u0131ra Nadir Hastal\u0131klar alan\u0131nda uzman hekimler ve hasta derne\u011finden temsilcilerin de anlaml\u0131 katk\u0131lar\u0131 oldu. Farkl\u0131 disiplinlerin bir araya gelmesi ile hayata ge\u00e7irdi\u011fimiz bu proje, \u00e7ok inand\u0131\u011f\u0131m\u0131z ve bizi ger\u00e7ekten \u00e7ok heyecanland\u0131ran bir olu\u015fuma d\u00f6n\u00fc\u015ft\u00fc ve ald\u0131\u011f\u0131m\u0131z geri d\u00f6n\u00fc\u015fler bize daha fazla \u00e7abalamam\u0131z i\u00e7in ilham oluyor. <\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Bug\u00fcn d\u00fcnyada milyonlarca insan nadir hastal\u0131klar ile m\u00fccadele ediyor.\u00dclkemizde ise yakla\u015f\u0131k 6 milyon ki\u015finin bu hastal\u0131klardan etkilendi\u011fi tahmin ediliyor.\u00a0Nadir hastal\u0131klar\u0131n te\u015fhisine ve tedavisine giden yolda fark\u0131ndal\u0131k son derece b\u00fcy\u00fck bir \u00f6neme sahip. Sanofi \u00d6zellikli Tedaviler T\u00fcrkiye, Levant ve \u0130ran Genel M\u00fcd\u00fcr\u00fc Pelin Yunuso\u011flu, Sanofi \u00d6zellikli Tedaviler T\u00fcrkiye, Levant ve \u0130ran Medikal Direkt\u00f6r\u00fc Dr. Nurdan Bulur …<\/p>\n","protected":false},"author":1,"featured_media":2939,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/posts\/2911"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/comments?post=2911"}],"version-history":[{"count":44,"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/posts\/2911\/revisions"}],"predecessor-version":[{"id":2968,"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/posts\/2911\/revisions\/2968"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/media\/2939"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/media?parent=2911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/categories?post=2911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/wp-json\/wp\/v2\/tags?post=2911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}